ID   HepG2 hALR
AC   CVCL_W371
DR   cancercelllines; CVCL_W371
DR   Wikidata; Q54882845
RX   PubMed=23797278;
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Transfected with: HGNC; 4236; GFER.
CC   Derived from site: In situ; Liver; UBERON=UBERON_0002107.
DI   NCIt; C3728; Hepatoblastoma
DI   ORDO; Orphanet_449; Hepatoblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0027 ! Hep-G2
SX   Male
AG   15Y
CA   Cancer cell line
DT   Created: 16-04-14; Last updated: 05-10-23; Version: 14
//
RX   PubMed=23797278; DOI=10.1007/s13577-013-0068-5;
RA   Liu H.-L., You S.-L., Rong Y.-H., Wu Y.-C., Zhu B., Wan Z.-H.,
RA   Liu W.-S., Mao P.-Y., Xin S.-J.;
RT   "The newly established human liver cell line: a potential cell source
RT   for the bioartificial liver in the future.";
RL   Hum. Cell 26:155-161(2013).
//